The Chicago-based company raised $110 million in its Series E financing and plans to use its funds to extend its focus beyond oncology treatment, and into cardiovascular diseases and diabetes.
Groupon Cofounder’s Health Startup Hits $2 Billion Valuation With Latest Funding Round
